Subsequently, CAPSTONE-1 and ASTRUM-005 study refreshed the median OS (mOS) of ES-SCLC to more than 15 months by programmed cell death 1 ligand 1 (PD-L1) inhibitor Adebrelimab combined with chemotherapy (14) or programmed cell death protein 1 (PD-1) inhibitor Serplulimab combined with Etoposide and Carboplatin (EC) (15). Here, CD274 is linked to small cell lung carcinoma.